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doi:10.1016/j.gmbhs.2012.03.002Abstract Type II diabetes mellitus (T2DM) is one of the most common underdiagnosed meta-
bolic diseases due to lack of recognizable symptoms in the early stage. T2DM can be largely
prevented or controlled by diet or regular exercise at early stages, but often goes undetected
for years, causing high rates of complications and mortality. Hence, a valid noninvasive early
detection approach is urgently needed. In this study, we explored noninvasive detection of
T2DM by salivary transcriptomic diagnostics. Salivary mRNA biomarkers were discovered by
comparing microarray profiles of salivary transcriptomes in 13 T2DM patients and 13 healthy
controls. The marker candidates selected from the microarray analysis were then subjected
to verification in the original 26 samples using reverse transcription quantitative real-time
polymerase chain reaction. Four up-regulated and two down-regulated mRNA biomarkers were
validated. The logistic regression model showed that the combination of four identified
biomarkers (KRAS, SAT1, EGFR, and PSMB2) could significantly distinguish T2DM patients from
the healthy controls, yielding a receiver-operating characteristic-plot area-under-the-curve
value of 0.917 with 100% sensitivity and 77% specificity. In conclusion, RNA signatures in salivaentistry and Dental Research Institute, University of California Los Angeles, 73-017 CHS, 10833 Le
, USA.
.T. Wong).
an Genomic Medicine and Biomarker Society. Published by Elsevier Taiwan LLC. All rights reserved.
8 Y.-H. Lee et al.Table 1 Demographic informati
Demographic variable C
Age (y) M
Female, n (%) F
Ethnicity, n (%) H
Smoking, n (%) P
C
SD Z standard deviation; T2DM Z tcould serve as biomarkers for the detection of T2DM with high sensitivity and specificity, and
offer a feasible means for early T2DM detection.
Copyright ª 2012, Taiwan Genomic Medicine and Biomarker Society. Published by Elsevier
Taiwan LLC. All rights reserved.Figure 1 Schematic diagram representing the experimental
design. HCZ healthy control; RT-qPCRZ reverse transcription
quantitative real-time polymerase chain reaction;
T2DM Z type II diabetes mellitus.Introduction
Diabetes mellitus is a metabolic disease characterized by
high blood glucose level resulting from insulin resistance
and/or b-cell dysfunction. Type II diabetes mellitus (T2DM)
is the most common form of diabetes, accounting for
90e95% of diabetics,1 and is a chronic disease often
preceded by a long asymptomatic period. The onset of
T2DM is usually insidious and often recognized only after
the development of complications. The period of undiag-
nosed durations increases the risk of many long-term health
complications.2e4 Although the diagnostics based on serum
glucose are standard (i.e., impaired glucose tolerance or
impaired fasting glucose), they are not used routinely at
annual physical examinations due to inconvenience and
invasiveness.
Saliva (oral fluid) is a mirror of the body since it could be
used to monitor the general health and the onset of specific
diseases.5 With collective efforts in the last decade, use of
oral fluid as a tool of disease detection has been extended
beyond oral diseases6,7 to systemic diseases,8e10 thereby
exhibiting tremendous potential in clinical applications.
With the advantages of noninvasive accessibility and easy
operations, saliva-based diagnostic assays are worth eval-
uating for T2DM detection.
In this study, we attempted to discover salivary mRNA
biomarkers for T2DM detection using genome-wide method.
Materials and methods
Sample collection
This study was conducted at the University of California,
Los Angeles (UCLA; USA), and Dental Research Institute and
University of Puerto Rico, School of Dental Medicine (Puerto
Rico), with approved Institute Review Boards for both
institutions. All participants were selected and recruited
from the database of a previous metabolic syndromeon of clinical samples used in t
haracteristics
T2DM
ean  SD 58.92
emale 11 (85
ispanic 13 (10
ast smoking 2 (15%
urrent smoking 3 (23%
ype II diabetes mellitus.prevalence study conducted by Dr Cynthia Perez and
coworkers. Participants were recruited from a random
sample of Puerto Ricans, aged 21e79 years, from the San
Juan metropolitan area. Diabetes was diagnosed if the
participant had an elevated fasting glucose level
(5.6 mmol/L) or was on drug treatment for elevated
glucose. A total of 40 saliva samples were collected. A total
of 26 saliva samples from 13 T2DM patients and 13 healthy
controls with similar age, ethnicity, gender, and smokinghe discovery and verification of salivary biomarker study.
Discovery/verification
(n Z 13) Healthy control (n Z 13) p
 10.59 49.85  12.92 0.062
%) 11 (85%) 1
0%) 13 (100%) 1
) 2 (15%) 1
) 3 (23%) 1
Detection type II diabetes saliva RNA biomarkers 9status were selected for the study (Table 1). All partici-
pants were free of cardiovascular disease and were
Hispanics. Participants provided written informed consent.
T2DM was diagnosed from fasting glucose, and history of
previous diagnosis and diabetes medication use.Biomarker discovery and verification
This study consisted of discovery and preliminary verifica-
tion of biomarkers as presented in Fig. 1. The procedures of
unstimulated saliva collection and cell-free saliva super-
natant harvesting followed the standard procedures, as
reported previously.11 Salivary mRNA of each sample was
isolated from 300 mL cell-free saliva supernatant using
MagMAX Viral RNA Isolation Kit (Applied Biosystems, FosterTable 2 Primers of six salivary biomarkers and three SIR genes
Gene symbol NCBI accession no. Prim
KRAS NM_033360 OF:
OR:
IF: g
IR: t
SLC13A2 NM_001145975 OF:
OR:
IF: g
IR: c
SAT1 NM_002970 OF:
OR:
IF: g
IR: g
TMEM72 NM_001123376 OF:
OR:
IF: c
IR: c
PSMB2 NM_002794 OF:
OR:
IF: a
IR: a
EGFR NM_005228 OF:
OR:
IF: c
IR: g
GAPDH b NM_002046 OF:
OR:
IF: a
IR: c
ACTB b NM_001101 OF:
OR:
IF: c
IR: a
RPS9 b NM_001013 OF:
OR:
IF: c
IR: c
FZ forward; IZ inner; NCBIZ National Center for Biotechnology Inf
a Amplicon size was presented as the PCR product size after using I
b SIR genes.City, CA, USA), as instructed by the product manual. The
quality of salivary mRNA was assessed by detecting
expression levels of three saliva internal reference (SIR)
genes (GAPDH, ACTB, and RPS9) using reverse transcription
quantitative real-time polymerase chain reaction (RT-
qPCR).12 The salivary transcriptomes in 13 T2DM patients
and 13 healthy controls were profiled by HG U133-Plus-2.0
array (Affymetrix, Santa Clara, CA, USA), following the
analysis by software of R-2.7.0 and Bioconductor-2.3.
Hits identified from the microarray data were verified in
original 26 samples using two-step SYBR Green-based RT-
qPCR (nested RT-qPCR).8e10 All used primers had intron-
spanning design and are described in Table 2. For each
biomarker candidate, RT-qPCR was performed in triplicate,
and the results (quantification cycle value; Cq) were
normalized by the arithmetic mean Cq value of three SIR.
er sequences (50 to 30) Amplicon sizea (bp)
ggctcaggacttagcaagaagttat
catctttgctcatcttttctttatgtt
aattccttttattgaaacatcagca
gttttcgaatttctcgaactaatg
85
catggatgtgaggggtgtg
gagagggcatgttgtattgtctgt
tgacgtgaggctatctgagg
gtgtgcactgtccaacatac
74
tgatgagtgattatagaggctttgg
gttcattccattctgctaccaag
aggctttggcataggatca
ctaccaagaagtgcatgctg
88
ggcctacctgctgctgtc
ctttcctcttcttccgcttg
ttcctccacccggtcct
gcttgctcagaaggaagtagg
90
gaccgatactacacaccgactatct
aatgattcgaacactgaaggttg
cgtgagagggcagtgga
ggttggcagattcaggatg
77
gcatacagtgccacccaga
ggcaggtcttgacgcagt
tgcctcaggccatgaac
ggccgtcaatgtagtgg
80
cctcaacgaccactttgtca
agttgggccatgaggtcc
ccactttgtcaagctcatttcct
accctgttgctgtagccaaat
59
gatcattgctcctcctgagc
cggactcgtcatactcctgc
tcctgagcgcaagtactcc
tactcctgcttgctgatccac
92
atctcgtctcgaccaagagc
tttgaccctccagacctcac
gaccaagagctgaagctgat
cagacctcacgtttgttcc
58
ormation; OZ outer; R, reverse; SIRZ saliva internal reference.
F þ IR primers.
10 Y.-H. Lee et al.genes for subsequent quantitative calculations. Statistical
analysis was conducted at a significant level of p < 0.05,
based on the Wilcoxon signed-rank test. The receiver
operating characteristic (ROC) curve and value of the area
under the curve (AUC) of each marker were processed by
software of MedCalc. The clinical utilities of the verified
biomarkers were evaluated by logistic regression model, as
reported previously.8e10Results and discussion
Isolated salivary mRNA of each sample was evaluated prior
to its use. An average of 104.35  28.71 ng (n Z 26) of
mRNA molecules were obtained from 300 mL of cell-free
saliva supernatant for each sample. There was no signifi-
cant difference in total isolated mRNA amount between
T2DM and control groups (p < 0.05, n Z 26). RT-qPCR
results showed that all saliva samples contained three SIR
genes, and the expression levels of these three SIR genes
were all similar between T2DM and healthy samples
(p Z 0.58, 0.11, and 0.43 for GAPDH, ACTB, and RPS9,
respectively; n Z 26).
Microarray results revealed the presence of 274 up-
regulated and 70 down-regulated genes in the saliva of
T2DM patients as compared to the results of healthy
controls (n Z 26; criteria: p < 0.05; >2-fold up/down-
regulation). Those genes were unlikely to be attributed
by chance (c2 test, p < 0.001) because the false-positive
rate was considered with p < 0.05. To seek a small
number of biomarkers that can discriminate T2DM truly, we
employed a more stringent cutoff of p < 0.02 and obtained
28 mRNA biomarker candidates, including 16 up-regulated
and 12 down-regulated transcripts.
Twenty-eight biomarker candidates selected from the
microarray analysis were then verified by the discovery-
phase sample cohort (n Z 26) using RT-qPCR. The Cq data
confirmed that the relative expression levels of 28 genes
were consistent with the microarray results (up/down-
regulation), and six of 28 showed significantly different
expression level between T2DM and healthy groups
(p < 0.05; n Z 26), including four (KRAS, SAT1, SLC13A2,Table 3 qPCR and ROC curve analyses of six identified salivary
Gene symbol T2DM (n Z 13)
DDCq a AUC (95% CI) p
KRAS 1.487 0.728 0.035
SLC13A2 3.799 0.769 0.032
SAT1 1.08 0.799 0.006
TMEM72 1.993 0.692 0.031
PSMB2 4.772 0.728 0.039
EGFR 2.972 0.746 0.034
AUCZ area under curve; CqZ quantification cycle value; qPCRZ q
characteristic; SIR Z saliva internal reference; T2DM Z type II diabe
a DDCq Z Mean normalized Cq value of 13 T2DM samples e mean
value of each gene was normalized by the arithmetic mean Cq value
b SL p Z significance-level p.and TMEM72) up-regulated and two (EGFR and PSMB2)
down-regulated genes that yielded a 21% of verification
rate. As shown in Table 3, all six genes exhibit 2-fold
change of up/down-regulation (DDCq > 1), and the ROC-
plot AUC values of the six markers are in the range of
0.692e0.799.
A single biomarker is unlikely to detect a specific disease
with both high specificity and high sensitivity (Table 3). To
evaluate the clinical utility of identified biomarkers,
logistic regression model was performed to assess the
capability of T2DM discrimination for different marker
combinations. Our results showed that the combination of
four biomarkers (KRAS, SAT1, EGRF, and PSMB2) can provide
the most robust power of T2DM discrimination based on the
highest ROC-plot AUC value of 0.917 (95% CI: 0.809e1.000;
Fig. 2A) with 100% sensitivity and 77% specificity by using
a cutoff value of 0.245 (Figs. 2A and 2B). In addition, the
participants recruited in this study had similar age, gender,
ethnicity, and history of smoking, in both T2DM and healthy
groups (Table 1). None of the confounding factors (i.e.,
demographic variables) affected the identified biomarkers
significantly (p > 0.05), indicating that the presence of
T2DM plays the key role for the variation of the biomarker’s
expression.
In this study, we demonstrated that saliva can be
a source of T2DM biomarkers since the salivary tran-
scriptomic profiles exhibited significant difference between
T2DM and healthy samples. However, it is unclear how
mRNA biomarkers circulating in the blood enter into saliva.
The molecular transport between serum and saliva was long
considered to occur through transcellular (e.g., passive
intracellular diffusion and active transport) or paracellular
routes (e.g., extracellular ultrafiltration).13,14 Although the
exact mechanism between salivary biomarkers and the
specific disease is still indefinite, the fact that salivary RNA
profile will change along with the disease development has
been demonstrated.15 Here we hypothesize that, upon
transporting into salivary glands, T2DM-related mediators
(e.g., hormones and/or cytokines) modulate the activities
and gene expression patterns of the salivary glands,
yielding surrogate salivary biomarker profiles. However,
those biomarkers do not necessarily reflect genetictranscriptomic biomarkers.
versus healthy control (n Z 13)
Sensitivity (%) Specificity (%) SL p b (area Z 0.5)
84.6 69.2 0.0317
69.2 84.6 0.0074
69.2 76.9 <0.001
46.2 100 0.0923
69.2 76.9 0.0315
100 46.2 0.0171
uantitative polymerase chain reaction; ROCZ receiver operating
tes mellitus.
normalized Cq value of 13 healthy controls. For each sample, Cq
of three SIR genes.
Figure 2 (A) ROC curve analysis of the four salivary mRNA
biomarkers combination (KRAS, SAT1, EGRF, and PSMB2) using
logistic regression approach. The table presents clinical
performances of the makers combination calculated based on
the cutoff point of 0.245 (nZ 26). (B) Interactive dot diagram
of the four salivary mRNA biomarkers combination (KRAS,
SAT1, EGRF, and PSMB2) obtained from normalized Cq values
(nZ 26). The horizontal line indicates the cutoff point (0.245),
with the minimal false-negative and false-positive results
between T2DM (n Z 13) and control groups (n Z 13).
Cq Z quantification cycle value; ROC Z receiver operating
characteristic; T2DM Z type II diabetes mellitus.
Detection type II diabetes saliva RNA biomarkers 11expression of diabetes mellitus. Further investigations are
required to corroborate these findings and understand their
mechanisms.
Conclusions
The long-term objective of this study is to develop a saliva-
based approach for early detection of T2DM and pre-
diabetes. In this study, we have established a prediction
model for salivary transcriptomic detection of T2DM, and
identified six salivary mRNA biomarkers that may have the
potential to impact current blood glucose-based diagnostics
for T2DM. However, owing to modest sample size and lack
of comprehensive validation studies, we consider that this
work was set as a preliminary proof-of-concept study.Further investigations need to be conducted to fully
address the potential predictive value of the RNA signatures
identified.
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